The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEden Regulatory News (EDEN)

Share Price Information for Eden (EDEN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 4.275
Bid: 4.15
Ask: 4.40
Change: -0.025 (-0.58%)
Spread: 0.25 (6.024%)
Open: 4.30
High: 4.325
Low: 4.275
Prev. Close: 4.30
EDEN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Result of AGM

30 Jun 2023 09:17

RNS Number : 5414E
Eden Research plc
30 June 2023
 

30 June 2023

 

 

Eden Research

("Eden" or "the Company")

 

Result of Annual General Meeting

 

Eden Research plc (AIM: EDEN), the AIM-quoted company focused on sustainable biopesticides and plastic-free formulation technology for use in the global crop protection, animal health and consumer products industries, is pleased to announce that all resolutions put forward to shareholders at the Company's Annual General Meeting held yesterday were duly passed.

 

The total number of votes received by proxy on each resolution, as more fully disclosed in the Notice of Meeting available on the Company's website, was as follows:

 

#

Resolution

For

%

Against

%

Withheld

1

To lay the 2022 Annual Report

131,946,591

100

-

-

180,000

2

Re-appoint auditors

131,921,591

99.98

25,000

0.02

180,000

3

Elect Richard Horsman

131,812,391

100

-

-

314,200

4

Re-elect Robin Cridland

131,901,591

100

-

-

225,000

5

Grant authority to the Directors to allot Ordinary Shares

131,904,060

99.86

186,281

0.14

36,250

6

Disapply statutory pre-emption rights on allotment of shares*

131,756,753

99.72

363,588

0.28

6,250

 

Notes:

· * denotes Special Resolution.

· A vote Withheld is not a vote in law and is not counted in the calculation of the votes cast For or Against the resolution, nor in the calculation of the percentage of issued share capital voted for any resolution.

· Votes For and Against are expressed as a percentage of votes validly cast for that resolution by proxy, excluding any Withheld votes.

 

 

For further information contact:

 

Eden Research plc

www.edenresearch.com

Sean SmithAlex Abrey

 

01285 359 555

Cenkos Securities plc (Nominated advisor and broker)

 

Giles Balleny / Max Gould (corporate finance)Michael Johnson (sales)

 

020 7397 8900

Hawthorn Advisors (Financial PR)

 

Simon Woods

Felix Meston

eden@hawthornadvisors.com

 

 

 

 

Notes to Editors:

 

Eden Research is the only UK-listed company focused on biopesticides for sustainable agriculture. It develops and supplies innovative biopesticide products and natural microencapsulation technologies to the global crop protection, animal health and consumer products industries. 

 

Eden's products are formulated with terpene active ingredients, based on natural plant defence metabolites. To date, they have been primarily used on high-value fruits and vegetables, improving crop yields and marketability, with equal or better performance when compared with conventional pesticides. Eden has two products currently on the market: 

 

Based on plant-derived active ingredients, Mevalone ® is a foliar biofungicide which initially targets a key disease affecting grapes and other high-value fruit and vegetable crops. It is a useful tool in crop defence programmes and is aligned with the requirements of integrated pest management programmes. It is approved for sale in a number of key countries whilst Eden and its partners pursue regulatory clearance in new territories thereby growing Eden's addressable market globally.

 

Cedroz ™ is a bionematicide that targets free living nematodes which are parasitic worms that affect a wide range of high-value fruit and vegetable crops globally. Cedroz is registered for sale on two continents and Eden's commercial collaborator, Eastman Chemical, is pursuing registration and commercialisation of this important new product in numerous countries globally.

 

Eden's Sustaine® encapsulation technology is used to harness the biocidal efficacy of naturally occurring chemicals produced by plants (terpenes) and can also be used with both natural and synthetic compounds to enhance their performance and ease-of-use. Sustaine microcapsules are naturally-derived, plastic-free, biodegradable micro-spheres derived from yeast. It is one of the only viable, proven and immediately registerable solutions to the microplastics problem in formulations requiring encapsulation.

 

Eden was admitted to trading on AIM on 11 May 2012 and trades under the symbol EDEN. It was awarded the London Stock Exchange Green Economy Mark in January 2021, which recognises London-listed companies that derive over 50% of their total annual revenue from products and services that contribute to the global green economy. Eden derives 100% of its total annual revenues from sustainable products and services. 

 

For more information about Eden, please visit: www.edenresearch.com.

 

Follow Eden on LinkedInTwitter and YouTube

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RAGFMMPTMTBJMJJ
Date   Source Headline
15th Feb 20131:59 pmRNSHolding(s) in Company
15th Feb 201310:14 amRNSHolding(s) in Company
15th Feb 201310:00 amRNSHolding(s) in Company
8th Feb 20137:00 amRNSPlacing to raise £1.1m
4th Dec 201212:25 pmRNSDirector/PDMR Shareholding
4th Dec 20127:00 amRNSDirectorate Change
29th Nov 20127:00 amRNSChange of Adviser
27th Nov 20127:00 amRNSAustralian Patent Expansion
9th Nov 20127:00 amRNSNotice of Acceptance of patent in Australia
17th Oct 201210:30 amRNSEU registration milestone reached
27th Sep 20127:00 amRNSHalf Yearly Report
13th Sep 20127:55 amRNSUpdate on Certis Europe
14th Jun 20127:00 amRNSDirector/PDMR Shareholding
12th Jun 201210:43 amRNSResult of AGM
12th Jun 20127:00 amRNSAGM Statement and Business Update
21st May 20124:03 pmRNSPublication of Annual Report and AGM Details
17th May 20121:40 pmRNSHolding(s) in Company
17th May 201211:25 amRNSGrant of Patent
11th May 20128:00 amRNSAIM Admission

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.